Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
BIAF

BIAF - bioAffinity Technologies, Inc. Stock Price, Fair Value and News

2.35USD-0.08 (-3.29%)Market Closed

Market Summary

BIAF
USD2.35-0.08
Market Closed
-3.29%

BIAF Stock Price

View Fullscreen

BIAF RSI Chart

BIAF Valuation

Market Cap

27.4M

Price/Earnings (Trailing)

-3.27

Price/Sales (Trailing)

5.55

EV/EBITDA

-3.15

Price/Free Cashflow

-3.98

BIAF Price/Sales (Trailing)

BIAF Profitability

Operating Margin

99.99%

EBT Margin

-169.16%

Return on Equity

-159.14%

Return on Assets

-103.94%

Free Cashflow Yield

-25.14%

BIAF Fundamentals

BIAF Revenue

Revenue (TTM)

4.9M

Rev. Growth (Yr)

17.7K%

Rev. Growth (Qtr)

8.72%

BIAF Earnings

Earnings (TTM)

-8.4M

Earnings Growth (Yr)

-27.99%

Earnings Growth (Qtr)

17.33%

Breaking Down BIAF Revenue

Last 7 days

-6%

Last 30 days

19.9%

Last 90 days

-15.8%

How does BIAF drawdown profile look like?

BIAF Financial Health

Current Ratio

2.22

BIAF Investor Care

Shares Dilution (1Y)

36.84%

Diluted EPS (TTM)

-0.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20244.9M000
2023636.7K1.3M1.9M2.5M
20220004.8K

Tracking the Latest Insider Buys and Sells of bioAffinity Technologies, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jul 01, 2024
platt jamie
acquired
-
-
33,784
-
Jul 01, 2024
joyce roby
acquired
-
-
33,784
-
Jul 01, 2024
rubin gary d
acquired
-
-
33,784
-
Jul 01, 2024
girgenti steven
acquired
-
-
33,784
executive chairman
Jul 01, 2024
knight peter s
acquired
-
-
33,784
-
Jul 01, 2024
diamond stuart
acquired
-
-
33,784
-
Jul 01, 2024
zannes maria
acquired
-
-
33,784
president & ceo
Jul 01, 2024
anderson robert a.
acquired
-
-
33,784
-
Jun 12, 2024
platt jamie
acquired
-
-
8,296
-
Jun 12, 2024
girgenti steven
acquired
-
-
8,296
executive chairman

1–10 of 50

Which funds bought or sold BIAF recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 15, 2024
ARMISTICE CAPITAL, LLC
unchanged
-
138,653
156,204
-%
May 15, 2024
STATE STREET CORP
unchanged
-
9,328
35,552
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
sold off
-100
-8.00
-
-%
May 15, 2024
Tower Research Capital LLC (TRC)
added
13.04
2,405
6,761
-%
May 15, 2024
CAPTRUST FINANCIAL ADVISORS
reduced
-30.09
-2,323
56,328
-%
May 15, 2024
TWO SIGMA INVESTMENTS, LP
sold off
-100
-31,825
-
-%
May 15, 2024
CITADEL ADVISORS LLC
reduced
-0.82
16,178
18,860
-%
May 14, 2024
Sheaff Brock Investment Advisors, LLC
new
-
20,200
20,200
-%
May 14, 2024
Qube Research & Technologies Ltd
unchanged
-
20.00
77.00
-%
May 14, 2024
NORTHERN TRUST CORP
new
-
27,597
27,597
-%

1–10 of 22

Are Funds Buying or Selling BIAF?

Are funds buying BIAF calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BIAF
No. of Funds

Recent SEC filings of bioAffinity Technologies, Inc.

View All Filings
Date Filed Form Type Document
Jul 09, 2024
8-K
Current Report
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jul 02, 2024
4
Insider Trading
Jun 14, 2024
4
Insider Trading

Peers (Alternatives to bioAffinity Technologies, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
186.1B
23.7B
-1.16% 17.67%
42.27
7.84
-8.94% -35.91%
41.0B
3.7B
-1.52% -9.28%
47.33
11.01
8.57% 23.94%
39.0B
6.6B
1.30% 11.70%
31.37
5.91
-6.38% -8.07%
16.5B
9.3B
8.39% 5.81%
19.5
1.78
-3.29% 6.68%
13.6B
1.2B
-0.04% 126.79%
-37.09
11.22
39.26% 33.08%
13.5B
2.0B
10.36% 75.16%
43.32
6.9
25.57% 21.62%
11.5B
4.1B
7.06% 10.82%
25.86
2.8
0.49% -10.45%
MID-CAP
9.1B
2.5B
19.45% -49.67%
-37.92
3.59
15.21% 53.51%
4.0B
603.7M
6.75% -14.04%
-8.64
6.6
25.21% 30.68%
3.8B
929.2M
4.77% -23.44%
2.4K
4.1
28.93% 111.61%
SMALL-CAP
953.1M
275.1M
35.16% 77.50%
-5.2
3.46
-13.93% -126.97%
94.1M
31.1M
16.81% -87.65%
-1.22
3.02
0.95% 19.75%
17.2M
9.0M
-21.14% -65.24%
-1.17
1.91
4.46% 45.80%
423.4K
5.5M
-6.52% -72.26%
-0.03
0.08
-68.52% -143.74%
183.8K
-
-50.00% -94.83%
-0.01
0.01
- -

bioAffinity Technologies, Inc. News

Latest updates
Defense World10 Jul 202407:57 am
Business Wire2 months ago

bioAffinity Technologies, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q2
Revenue8.7%2,406,3912,213,356298,48419,73813,5427,3461,1501,306
Cost Of Revenue---74,7041,23487.00-146146
Gross Profit---223,78018,504834-1,0041,160
Operating Expenses-6.0%4,351,6214,631,7422,518,2841,796,8541,558,8911,626,379977,160685,279
  S&GA Expenses-0.8%2,185,9442,203,1702,023,9171,426,4691,147,8751,133,756595,702408,620
  R&D Expenses-9.1%393,639432,818330,376335,125369,617501,301319,744248,419
EBITDA Margin46.8%-1.60-3.01-3.69-6.94-10.66-1,167--
Interest Expenses-7.0%23,55025,3258,7851,3601,65589,290896,502399,265
Income Taxes60.1%3,6722,2932,2944,58711,819-1.00300-
Earnings Before Taxes17.4%-1,958,143-2,370,871-2,288,590-1,735,586-1,520,971-1,674,583-4,919,158-88,052
EBT Margin45.9%-1.69-3.13-3.80-7.76-12.88-1,697--
Net Income17.3%-1,961,815-2,373,164-2,290,884-1,740,173-1,532,790-1,674,583-4,919,458-88,052
Net Income Margin45.9%-1.69-3.13-3.81-7.78-12.90-1,697--
Free Cashflow-48.9%-2,387,362-1,602,861-1,532,682-1,363,810-1,561,355---
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32021Q4
Assets-2.1%8,0498,22210,1898,87310,46512,18214,0631,453
  Current Assets-1.0%3,9313,9736,0108,65910,23311,96214,0551,438
    Cash Equivalents-13.1%2,4532,8224,5098,2799,80011,41413,5001,361
  Inventory-48.7%9.0018.0010.0010.0011.006.006.00-
  Net PPE0.6%4614595122072252142.005.00
  Goodwill0%1,4041,4041,404-----
Liabilities-17.1%2,7923,3663,1967757961,1391,46413,200
  Current Liabilities-21.2%1,7722,2481,9597757961,1391,46413,040
Shareholder's Equity8.3%5,2574,8556,9948,0989,66811,04312,599-
  Retained Earnings-4.5%-46,600-44,604-42,231-39,940-38,200-36,667-34,992-28,513
  Additional Paid-In Capital4.8%51,74549,39449,16147,97947,80947,65247,53312,704
Shares Outstanding19.4%11,2169,3959,2178,5218,4348,3813,1952,677
Float----14,000----
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-45.1%-2,345-1,616-1,532-1,359-1,529-1,300-1,760-376-633--
  Share Based Compensation21.0%28423518617015837.0079.0027.00106--
Cashflow From Investing-407.9%-41.3913.00-2,186-3.86-32.31------
Cashflow From Financing2480.7%2,019-84.80-50.77-126-83.32-56315,044-437301--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

BIAF Income Statement

2024-03-31
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Net Revenue$ 2,406,391$ 921
Operating expenses:  
Direct costs and expenses1,573,44187
Research and development393,639369,617
Clinical development48,96019,628
Selling, general and administrative2,185,9441,147,875
Depreciation and amortization149,63721,684
Total operating expenses4,351,6211,558,891
Loss from operations(1,945,230)(1,557,970)
Other income (expense):  
Interest income6,12738,654
Interest expense(23,550)(1,655)
Other expense4,510
Total other expense(12,913)36,999
Net loss before provision for income taxes(1,958,143)(1,520,971)
Income tax expense(3,672)(11,819)
Net loss$ (1,961,815)$ (1,532,790)
Net loss per common share, basic$ (0.20)$ (0.18)
Net loss per common share, diluted$ (0.20)$ (0.18)
Weighted average common shares outstanding, basic9,915,4268,433,689
Weighted average common shares outstanding, diluted9,915,4268,433,689

BIAF Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 2,453,165$ 2,821,570
Accounts and other receivables, net1,123,609811,674
Inventory9,48718,484
Prepaid expenses and other current assets344,900321,017
Total current assets3,931,1613,972,745
Non-current assets:  
Property and equipment, net461,209458,633
Operating lease right-of-use asset, net347,860370,312
Finance lease right-to-use, net1,069,6011,165,844
Goodwill1,404,4861,404,486
Intangible assets, net818,889833,472
Other assets16,06016,060
Total assets8,049,2668,221,552
Current liabilities:  
Accounts payable383,993604,789
Accrued expenses883,3191,149,811
Unearned revenue30,17433,058
Operating lease liability, current portion96,63194,708
Finance lease liability, current portion372,787365,463
Notes payable, current portion4,686
Total current liabilities1,771,5902,247,829
Non-current liabilities:  
Finance lease liability, net of current portion739,478835,467
Operating lease liability, net of current portion258,110283,001
Notes payable, net of current portion23,037
Total liabilities2,792,2153,366,297
Commitments and contingencies (See Note 11)
Stockholders’ equity:  
Preferred stock, par value $0.001 per share; 20,000,000 shares authorized; no shares issued or outstanding at March 31, 2024, and December 31, 2023
Common stock, par value $0.007 per share; 25,000,000 shares authorized; 11,216,491 and 9,394,610 issued and outstanding at March 31, 2024, and at December 31, 2023, respectively.78,51565,762
Additional paid-in capital51,744,83049,393,972
Accumulated deficit(46,566,294)(44,604,479)
Total stockholders’ equity5,257,0514,855,255
Total liabilities and stockholders’ equity$ 8,049,266$ 8,221,552
BIAF
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
 CEO
 WEBSITEbioaffinitytech.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES14

bioAffinity Technologies, Inc. Frequently Asked Questions


What is the ticker symbol for bioAffinity Technologies, Inc.? What does BIAF stand for in stocks?

BIAF is the stock ticker symbol of bioAffinity Technologies, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of bioAffinity Technologies, Inc. (BIAF)?

As of Wed Jul 17 2024, market cap of bioAffinity Technologies, Inc. is 27.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BIAF stock?

You can check BIAF's fair value in chart for subscribers.

What is the fair value of BIAF stock?

You can check BIAF's fair value in chart for subscribers. The fair value of bioAffinity Technologies, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of bioAffinity Technologies, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BIAF so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is bioAffinity Technologies, Inc. a good stock to buy?

The fair value guage provides a quick view whether BIAF is over valued or under valued. Whether bioAffinity Technologies, Inc. is cheap or expensive depends on the assumptions which impact bioAffinity Technologies, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIAF.

What is bioAffinity Technologies, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jul 17 2024, BIAF's PE ratio (Price to Earnings) is -3.27 and Price to Sales (PS) ratio is 5.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIAF PE ratio will change depending on the future growth rate expectations of investors.